A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies

NCT06820268 ↗

Phase 1 Recruiting 168 enrolled NovaOnco Therapeutics Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

Evaluation of the safety, tolerability, pharmacokinetics, and preliminary efficacy of XS-04 in patients with relapsed or refractory hematologic malignancies

Timeline

Start: 2025-01-14
Primary completion: 2027-11-01
Completion: 2028-03-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	XS-04	Unknown	1 mg	Oral
Subject	XS-04	Unknown	3 mg	Oral
Subject	XS-04	Unknown	10 mg	Oral
Subject	XS-04	Unknown	20 mg	Oral
Subject	XS-04	Unknown	40 mg	Oral
Subject	XS-04	Unknown	80 mg	Oral
Subject	XS-04	Unknown	120 mg	Oral
Subject	XS-04	Unknown	160 mg	Oral

A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies

Summary

Timeline

Drugs

Indications